Lomitapide (BioDeep_00000858523)

   


代谢物信息卡片


Lomitapide

化学式: C39H37F6N3O2 (693.2789814)
中文名称: 洛美他派
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
InChI: InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)

描述信息

C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent

同义名列表

1 个代谢物同义名

Lomitapide



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yangmin Zheng, Yue Hu, Ziping Han, Feng Yan, Sijia Zhang, Zhenhong Yang, Fangfang Zhao, Lingzhi Li, Junfen Fan, Rongliang Wang, Yumin Luo. Lomitapide ameliorates middle cerebral artery occlusion-induced cerebral ischemia/reperfusion injury by promoting neuronal autophagy and inhibiting microglial migration. CNS neuroscience & therapeutics. 2022 12; 28(12):2183-2194. doi: 10.1111/cns.13961. [PMID: 36052650]
  • Mohamed E M Saeed, Joelle C Boulos, Sabrina B Mücklich, Ellen Leich, Manik Chatterjee, Sabine M Klauck, Thomas Efferth. Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells. Cancer genomics & proteomics. 2022 Sep; 19(5):540-555. doi: 10.21873/cgp.20339. [PMID: 35985681]
  • Laura D'Erasmo, Kim Steward, Angelo Baldassare Cefalù, Alessia Di Costanzo, Eric Boersma, Simone Bini, Marcello Arca, Jeanine Roeters van Lennep. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European journal of preventive cardiology. 2022 05; 29(5):832-841. doi: 10.1093/eurjpc/zwab229. [PMID: 34971394]
  • Dirk J Blom, Daniel Gaudet, Robert A Hegele, Dharmesh S Patel, Jaimini Cegla, Genovefa Kolovou, Luis Masana Marin. A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in therapy. 2022 04; 39(4):1857-1870. doi: 10.1007/s12325-021-02031-y. [PMID: 35194765]
  • Undral Munkhsaikhan, Youngin Kwon, Amal M Sahyoun, Karima Ait-Aissa, Adam Kassan, Modar Kassan. The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity. Obesity (Silver Spring, Md.). 2022 04; 30(4):893-901. doi: 10.1002/oby.23389. [PMID: 35253407]
  • Vishal Patel, Amit Joharapurkar, Samadhan Kshirsagar, Maulik Patel, Hiren Patel, Hardikkumar Savsani, Mukul Jain. Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation. Toxicology and applied pharmacology. 2022 01; 434(?):115825. doi: 10.1016/j.taap.2021.115825. [PMID: 34902352]
  • Laura D'Erasmo, Antonio Gallo, Angelo Baldassare Cefalù, Alessia Di Costanzo, Samir Saheb, Antonina Giammanco, Maurizio Averna, Alessio Buonaiuto, Gabriella Iannuzzo, Giuliana Fortunato, Arturo Puja, Tiziana Montalcini, Chiara Pavanello, Laura Calabresi, Giovanni Battista Vigna, Marco Bucci, Katia Bonomo, Fabio Nota, Tiziana Sampietro, Francesco Sbrana, Patrizia Suppressa, Carlo Sabbà, Fabio Fimiani, Arturo Cesaro, Paolo Calabrò, Silvia Palmisano, Sergio D'Addato, Livia Pisciotta, Stefano Bertolini, Randa Bittar, Olga Kalmykova, Sophie Béliard, Alain Carrié, Marcello Arca, Eric Bruckert. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet journal of rare diseases. 2021 09; 16(1):381. doi: 10.1186/s13023-021-01999-8. [PMID: 34496902]
  • Julien Allard, Simon Bucher, Julie Massart, Pierre-Jean Ferron, Dounia Le Guillou, Roxane Loyant, Yoann Daniel, Youenn Launay, Nelly Buron, Karima Begriche, Annie Borgne-Sanchez, Bernard Fromenty. Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell biology and toxicology. 2021 04; 37(2):151-175. doi: 10.1007/s10565-020-09537-1. [PMID: 32535746]
  • James A Underberg, Christopher P Cannon, Dominique Larrey, Lukas Makris, Dirk Blom, Helen Phillips. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). Journal of clinical lipidology. 2020 Nov; 14(6):807-817. doi: 10.1016/j.jacl.2020.08.006. [PMID: 33023859]
  • Claudia Stefanutti. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Current atherosclerosis reports. 2020 06; 22(8):38. doi: 10.1007/s11883-020-00858-4. [PMID: 32557261]
  • Archna Bajaj, Marina Cuchel. Homozygous familial hypercholesterolemia: what treatments are on the horizon?. Current opinion in lipidology. 2020 06; 31(3):119-124. doi: 10.1097/mol.0000000000000677. [PMID: 32332430]
  • Irina Crismaru, Anca Pantea Stoian, Ovidiu Gabriel Bratu, Mihnea-Alexandru Gaman, Ana Maria Alexandra Stanescu, Nicolae Bacalbasa, Camelia Cristina Diaconu. Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids in health and disease. 2020 May; 19(1):85. doi: 10.1186/s12944-020-01275-x. [PMID: 32375792]
  • Laura D'Erasmo, Alessia Di Costanzo, Marcello Arca. Autosomal recessive hypercholesterolemia: update for 2020. Current opinion in lipidology. 2020 04; 31(2):56-61. doi: 10.1097/mol.0000000000000664. [PMID: 32011344]
  • Genovefa Kolovou, Olga Diakoumakou, Vana Kolovou, Epameinondas Fountas, Stavros Stratakis, Evangelos Zacharis, Evangelos N Liberopoulos, Fedra Matsouka, Alexandros Tsoutsinos, Irene Mastorakou, Theodoros Katsikas, Sophie Mavrogeni, Georgios Hatzigeorgiou. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. European journal of preventive cardiology. 2020 01; 27(2):157-165. doi: 10.1177/2047487319870007. [PMID: 31403880]
  • Antonina Giammanco, Angelo B Cefalù, Davide Noto, Maurizio R Averna. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Current medicinal chemistry. 2020; 27(23):3773-3783. doi: 10.2174/0929867326666190121120735. [PMID: 30663562]
  • Dirk J Blom, Frederick J Raal, Raul D Santos, A David Marais. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Current atherosclerosis reports. 2019 11; 21(12):48. doi: 10.1007/s11883-019-0809-3. [PMID: 31741187]
  • Etienne Khoury, Diane Brisson, Nathalie Roy, Gérald Tremblay, Daniel Gaudet. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert opinion on drug safety. 2019 05; 18(5):403-414. doi: 10.1080/14740338.2019.1602606. [PMID: 30945578]
  • Ana Paula M Chacra, Michael C Ferrari, Viviane Z Rocha, Raul D Santos. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Journal of clinical lipidology. 2019 May; 13(3):397-401. doi: 10.1016/j.jacl.2019.03.001. [PMID: 30948303]
  • Atsushi Nohara, Yoshihiko Otsubo, Koji Yanagi, Masayuki Yoshida, Katsunori Ikewaki, Mariko Harada-Shiba, Agnieszka Jurecka. Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. Journal of atherosclerosis and thrombosis. 2019 Apr; 26(4):368-377. doi: 10.5551/jat.45708. [PMID: 30259883]
  • Robert A Hegele, Sotirios Tsimikas. Lipid-Lowering Agents. Circulation research. 2019 02; 124(3):386-404. doi: 10.1161/circresaha.118.313171. [PMID: 30702996]
  • Noriko Kameyama, Chizuko Maruyama, Fuyuha Kitagawa, Kazunobu Nishii, Kaori Uenomachi, Yayoi Katayama, Hiromi Koga, Naoko Chikamoto, Yuko Kuwata, Junko Torigoe, Masako Arimoto, Toshiaki Tokumaru, Katsunori Ikewaki, Atsushi Nohara, Yoshihiko Otsubo, Koji Yanagi, Masayuki Yoshida, Mariko Harada-Shiba. Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia. Journal of atherosclerosis and thrombosis. 2019 Jan; 26(1):72-83. doi: 10.5551/jat.44107. [PMID: 29899183]
  • Frederick J Raal, G Kees Hovingh, Alberico L Catapano. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277(?):483-492. doi: 10.1016/j.atherosclerosis.2018.06.859. [PMID: 30270089]
  • Dirk J Blom, Marina Cuchel, Miranda Ager, Helen Phillips. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. Orphanet journal of rare diseases. 2018 06; 13(1):96. doi: 10.1186/s13023-018-0841-3. [PMID: 29925433]
  • Anil Can, Victor M Castro, Dmitriy Dligach, Sean Finan, Sheng Yu, Vivian Gainer, Nancy A Shadick, Guergana Savova, Shawn Murphy, Tianxi Cai, Scott T Weiss, Rose Du. Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture. Stroke. 2018 05; 49(5):1148-1154. doi: 10.1161/strokeaha.117.019972. [PMID: 29622625]
  • Simona Sperlongano, Felice Gragnano, Francesco Natale, Laura D'Erasmo, Claudia Concilio, Arturo Cesaro, Enrica Golia, Mario Crisci, Rossella Sperlongano, Fabio Fimiani, Mariagiovanna Russo, Marcello Arca, Giuseppe Limongelli, Paolo Calabrò. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. Journal of cardiovascular medicine (Hagerstown, Md.). 2018 03; 19(3):83-90. doi: 10.2459/jcm.0000000000000620. [PMID: 29389816]
  • Ezim Ajufo, Daniel J Rader. New Therapeutic Approaches for Familial Hypercholesterolemia. Annual review of medicine. 2018 01; 69(?):113-131. doi: 10.1146/annurev-med-051215-030943. [PMID: 29414257]
  • Robert Leipold, Frederick Raal, Jack Ishak, Kees Hovingh, Helen Phillips. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. European journal of preventive cardiology. 2017 11; 24(17):1843-1850. doi: 10.1177/2047487317730473. [PMID: 28925748]
  • Xin Liu, Peng Men, Yuhui Wang, Suodi Zhai, Zhigang Zhao, George Liu. Efficacy and Safety of Lomitapide in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2017 Aug; 17(4):299-309. doi: 10.1007/s40256-017-0214-7. [PMID: 28255870]
  • Mariko Harada-Shiba, Katsunori Ikewaki, Atsushi Nohara, Yoshihiko Otsubo, Koji Yanagi, Masayuki Yoshida, Qing Chang, Pamela Foulds. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia. Journal of atherosclerosis and thrombosis. 2017 Apr; 24(4):402-411. doi: 10.5551/jat.38216. [PMID: 28154305]
  • Jane I Won, Jun Zhang, Kristen M Tecson, Peter A McCullough. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. Reviews in cardiovascular medicine. 2017; 18(1):21-28. doi: 10.3909/ricm0834. [PMID: 28509890]
  • Michael France, Alan Rees, Dev Datta, Gilbert Thompson, Nigel Capps, Gordon Ferns, Uma Ramaswami, Mary Seed, Dermot Neely, Robert Cramb, Carol Shoulders, Mahmoud Barbir, Alison Pottle, Ruth Eatough, Steven Martin, Graham Bayly, Bill Simpson, Julian Halcox, Ray Edwards, Linda Main, Jules Payne, Handrean Soran. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016 12; 255(?):128-139. doi: 10.1016/j.atherosclerosis.2016.10.017. [PMID: 27839699]
  • Amanda J Brahm, Robert A Hegele. Lomitapide for the treatment of hypertriglyceridemia. Expert opinion on investigational drugs. 2016 Dec; 25(12):1457-1463. doi: 10.1080/13543784.2016.1254187. [PMID: 27785928]
  • W Virgil Brown, Dean A Bramlet, Joyce L Ross, James A Underberg. JCL roundtable: Risk evaluation and mitigation strategy. Journal of clinical lipidology. 2016 Nov; 10(6):1288-1296. doi: 10.1016/j.jacl.2016.10.007. [PMID: 27919344]
  • Peter P Toth. Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. The American journal of cardiology. 2016 Sep; 118(6 Suppl):19A-32A. doi: 10.1016/j.amjcard.2016.05.028. [PMID: 27620356]
  • Enrico Agabiti Rosei, Massimo Salvetti. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2016 Sep; 23(3):217-30. doi: 10.1007/s40292-016-0155-2. [PMID: 27567901]
  • Genovefa D Kolovou, Vana Kolovou, Anna Papadopoulou, Gerald F Watts. MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. Journal of atherosclerosis and thrombosis. 2016 Jul; 23(7):878-83. doi: 10.5551/jat.34777. [PMID: 27170061]
  • Claudia Stefanutti, Claudia Morozzi, Serafina Di Giacomo, Barbara Sovrano, Dario Mesce, Alberto Grossi. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. Journal of clinical lipidology. 2016 Jul; 10(4):782-789. doi: 10.1016/j.jacl.2016.02.009. [PMID: 27578108]
  • Jorg Taubel, Mark Sumeray, Ulrike Lorch, Andre McLean. Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese Subjects. Journal of atherosclerosis and thrombosis. 2016 May; 23(5):606-20. doi: 10.5551/jat.30452. [PMID: 26686567]
  • Dirk J Blom, Zahi A Fayad, John J P Kastelein, Dominique Larrey, Lukas Makris, Charles Schwamlein, LeAnne Bloeden, James Underberg. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. Journal of clinical lipidology. 2016 Mar; 10(2):273-82. doi: 10.1016/j.jacl.2015.11.011. [PMID: 27055957]
  • Jeffrey A Marbach, Jhapat Thapa, Edward Goldenberg, Danielle Duffy. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. Delaware medical journal. 2015 Aug; 87(8):238-43. doi: ". [PMID: 26402926]
  • Jeanine Roeters van Lennep, Maurizio Averna, Rodrigo Alonso. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Journal of clinical lipidology. 2015 Jul; 9(4):607-17. doi: 10.1016/j.jacl.2015.05.001. [PMID: 26228681]
  • NULL. Iomitapide (Lojuxta). Use only in homozygous familial hypercholesterolaemia, with caution. Prescrire international. 2015 Jul; 24(162):176-8. doi: NULL. [PMID: 26240881]
  • Amanda J Brahm, Robert A Hegele. Chylomicronaemia--current diagnosis and future therapies. Nature reviews. Endocrinology. 2015 Jun; 11(6):352-62. doi: 10.1038/nrendo.2015.26. [PMID: 25732519]
  • C Stefanutti, D J Blom, M R Averna, E A Meagher, H dT Theron, A D Marais, R A Hegele, C R Sirtori, P K Shah, D Gaudet, G B Vigna, B S Sachais, S Di Giacomo, A M E du Plessis, L T Bloedon, J Balser, D J Rader, M Cuchel. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis. 2015 Jun; 240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014. [PMID: 25897792]
  • Ioanna Gouni-Berthold, Heiner K Berthold. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Atherosclerosis. Supplements. 2015 May; 18(?):28-34. doi: 10.1016/j.atherosclerosissup.2015.02.005. [PMID: 25936301]
  • Amanda J Hooper, John R Burnett, Gerald F Watts. Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circulation research. 2015 Jan; 116(1):193-205. doi: 10.1161/circresaha.116.304637. [PMID: 25552696]
  • Anna Raper, Daniel M Kolansky, Bruce S Sachais, Emma A Meagher, Amanda L Baer, Marina Cuchel. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Journal of clinical lipidology. 2015 Jan; 9(1):107-12. doi: 10.1016/j.jacl.2014.08.005. [PMID: 25670368]
  • Evan A Stein, Frederick J Raal. New therapies for reducing low-density lipoprotein cholesterol. Endocrinology and metabolism clinics of North America. 2014 Dec; 43(4):1007-33. doi: 10.1016/j.ecl.2014.08.008. [PMID: 25432394]
  • Gautam Das, Alan Rees. Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol. Current opinion in lipidology. 2014 Dec; 25(6):471-3. doi: 10.1097/mol.0000000000000134. [PMID: 25370457]
  • Seth J Baum, E J G Sijbrands, Pedro Mata, Gerald F Watts. The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. Journal of clinical lipidology. 2014 Nov; 8(6):542-549. doi: 10.1016/j.jacl.2014.09.005. [PMID: 25499935]
  • Dave L Dixon, Evan M Sisson, Michael Butler, Ashley Higbea, Brendan Muoio, Brandy Turner. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. The Journal of cardiovascular nursing. 2014 Sep; 29(5):E7-E12. doi: 10.1097/jcn.0000000000000104. [PMID: 24231894]
  • Marina Cuchel, Dirk J Blom, Maurizio R Averna. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. Supplements. 2014 Sep; 15(2):33-45. doi: 10.1016/j.atherosclerosissup.2014.07.005. [PMID: 25257075]
  • Ada Cuevas, María Magdalena Farías, Rodrigo Alonso. [New lipid lowering agents]. Revista medica de Chile. 2014 Jul; 142(7):880-8. doi: 10.4067/s0034-98872014000700008. [PMID: 25378007]
  • Kyle A Davis, Marta A Miyares. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014 Jun; 71(12):1001-8. doi: 10.2146/ajhp130592. [PMID: 24865757]
  • Sony Tuteja, Danielle Duffy, Richard L Dunbar, Rajesh Movva, Ram Gadi, LeAnne T Bloedon, Marina Cuchel. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy. 2014 Mar; 34(3):227-39. doi: 10.1002/phar.1351. [PMID: 24734312]
  • Frank M Sacks, Maxine Stanesa, Robert A Hegele. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA internal medicine. 2014 Mar; 174(3):443-7. doi: 10.1001/jamainternmed.2013.13309. [PMID: 24366202]
  • Ioanna Gouni-Berthold, Heiner K Berthold. Familial hypercholesterolemia: etiology, diagnosis and new treatment options. Current pharmaceutical design. 2014; 20(40):6220-9. doi: 10.2174/1381612820666140620125213. [PMID: 24953396]
  • Alpo Vuorio, Matti J Tikkanen, Petri T Kovanen. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vascular health and risk management. 2014; 10(?):263-70. doi: 10.2147/vhrm.s36641. [PMID: 24851052]
  • Emil M deGoma. Lomitapide for the management of homozygous familial hypercholesterolemia. Reviews in cardiovascular medicine. 2014; 15(2):109-18. doi: 10.3909/ricm0735. [PMID: 25051128]
  • Amirhossein Sahebkar, Gerald F Watts. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?. Cardiovascular drugs and therapy. 2013 Dec; 27(6):559-67. doi: 10.1007/s10557-013-6479-4. [PMID: 23913122]
  • Manouchkathe Cassagnol, Danielle Ezzo, Priti N Patel. New therapeutic alternatives for the management of dyslipidemia. Journal of pharmacy practice. 2013 Dec; 26(6):528-40. doi: 10.1177/0897190013507582. [PMID: 24142496]
  • Borje Darpo, Georg Ferber, Meijian Zhou, Mark Sumeray, Philip Sager. Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2013 Nov; 18(6):577-89. doi: 10.1111/anec.12103. [PMID: 24118671]
  • Annette McDonough, Lea Ann Matura, Diane Carroll. New pharmacologic treatments for familial hypercholesterolemia. Nursing for women's health. 2013 Oct; 17(5):443-7. doi: 10.1111/1751-486x.12068. [PMID: 24138664]
  • Nathalie Nicod, Robert S Parker. Vitamin E secretion by Caco-2 monolayers to APOA1, but not to HDL, is vitamer selective. The Journal of nutrition. 2013 Oct; 143(10):1565-72. doi: 10.3945/jn.113.176834. [PMID: 23946344]
  • Adrian D Marais, Dirk J Blom. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Current opinion in lipidology. 2013 Aug; 24(4):288-94. doi: 10.1097/mol.0b013e32836308bc. [PMID: 23839331]
  • Caroline M Perry. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2013 Aug; 13(4):285-96. doi: 10.1007/s40256-013-0030-7. [PMID: 23720215]
  • Marina Cuchel, Daniel J Rader. Microsomal transfer protein inhibition in humans. Current opinion in lipidology. 2013 Jun; 24(3):246-50. doi: 10.1097/mol.0b013e32836139df. [PMID: 23594709]
  • M Ezzahti, E J G Sijbrands, M T Mulder, J E Roeters van Lennep. Familial hypercholesterolaemia: new treatment options. The Netherlands journal of medicine. 2013 Jun; 71(5):227-33. doi: ". [PMID: 23799308]
  • Anne C Goldberg. Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors. Journal of clinical lipidology. 2013 May; 7(3 Suppl):S16-20. doi: 10.1016/j.jacl.2013.03.003. [PMID: 23642324]
  • Marina Cuchel, Emma A Meagher, Hendrik du Toit Theron, Dirk J Blom, A David Marais, Robert A Hegele, Maurizio R Averna, Cesare R Sirtori, Prediman K Shah, Daniel Gaudet, Claudia Stefanutti, Giovanni B Vigna, Anna M E Du Plessis, Kathleen J Propert, William J Sasiela, LeAnne T Bloedon, Daniel J Rader. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet (London, England). 2013 Jan; 381(9860):40-6. doi: 10.1016/s0140-6736(12)61731-0. [PMID: 23122768]
  • Michael S Kostapanos, Evangelos C Rizos, Nikolaos Papanas, Efstratios Maltezos, Moses S Elisaf. Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias. Current pharmaceutical design. 2013; 19(17):3150-60. doi: 10.2174/1381612811319170023. [PMID: 23317403]
  • M Mahmood Hussain, Paul Rava, Meghan Walsh, Muhammad Rana, Jahangir Iqbal. Multiple functions of microsomal triglyceride transfer protein. Nutrition & metabolism. 2012 Feb; 9(?):14. doi: 10.1186/1743-7075-9-14. [PMID: 22353470]
  • Klaus G Parhofer. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core evidence. 2012; 7(?):29-38. doi: 10.2147/ce.s25239. [PMID: 22701100]
  • C Stefanutti, C Morozzi, S Di Giacomo. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Current medicinal chemistry. 2012; 19(28):4861-8. doi: 10.2174/092986712803341485. [PMID: 22963620]
  • B Sjouke, D M Kusters, J J P Kastelein, G K Hovingh. Familial hypercholesterolemia: present and future management. Current cardiology reports. 2011 Dec; 13(6):527-36. doi: 10.1007/s11886-011-0219-9. [PMID: 21938413]
  • Vipin Dhote, Amit Joharapurkar, Samadhan Kshirsagar, Nirav Dhanesha, Vishal Patel, Avnish Patel, Saurin Raval, Mukul Jain. Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats. Clinical and experimental pharmacology & physiology. 2011 May; 38(5):338-44. doi: 10.1111/j.1440-1681.2011.05513.x. [PMID: 21401695]
  • Manfredi Rizzo. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs : the investigational drugs journal. 2010 Feb; 13(2):103-11. doi: . [PMID: 20127562]
  • Richard Češka, Tomáš Štulc, Lucie Votavová, Lucie Schwarzová, Martina Vaclová, Tomáš Freiberger. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment]. Vnitrni lekarstvi. Fall 201; 62(11):887-894. doi: NULL. [PMID: 28128575]
  • Frederick F Samaha, James McKenney, Leanne T Bloedon, William J Sasiela, Daniel J Rader. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature clinical practice. Cardiovascular medicine. 2008 Aug; 5(8):497-505. doi: 10.1038/ncpcardio1250. [PMID: 18506154]
  • Marina Cuchel, LeAnne T Bloedon, Philippe O Szapary, Daniel M Kolansky, Megan L Wolfe, Antoine Sarkis, John S Millar, Katsunori Ikewaki, Evan S Siegelman, Richard E Gregg, Daniel J Rader. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. The New England journal of medicine. 2007 Jan; 356(2):148-56. doi: 10.1056/nejmoa061189. [PMID: 17215532]
  • Toshiyuki Funatsu, Hirotoshi Kakuta, Toshiyuki Takasu, Keiji Miyata. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor. European journal of pharmacology. 2002 Nov; 455(2-3):161-7. doi: 10.1016/s0014-2999(02)02611-0. [PMID: 12445582]
  • J A Robl, R Sulsky, C Q Sun, L M Simpkins, T Wang, J K Dickson, Y Chen, D R Magnin, P Taunk, W A Slusarchyk, S A Biller, S J Lan, F Connolly, L K Kunselman, T Sabrah, H Jamil, D Gordon, T W Harrity, J R Wetterau. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. Journal of medicinal chemistry. 2001 Mar; 44(6):851-6. doi: 10.1021/jm000494a. [PMID: 11300866]